FierceBiotech 8. Jan. 2026 WEP Clinical grabs European CRO Siron Clinical, broadening global capabilities
FierceBiotech 8. Jan. 2026 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
FierceBiotech 7. Jan. 2026 Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
FierceBiotech 7. Jan. 2026 Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
FierceBiotech 7. Jan. 2026 Staar Surgical's takeover saga ends as shareholder revolt stops Alcon’s attempted merger deal
FierceBiotech 7. Jan. 2026 Fierce Biotech Fundraising Tracker '26: Soley sees $200M series C; Rakuten rakes in $100M
FierceBiotech 7. Jan. 2026 Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing
FierceBiotech 7. Jan. 2026 GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push
FierceBiotech 6. Jan. 2026 Arrowhead takes aim at obesity market with early data on dual gene silencing assets
FierceBiotech 6. Jan. 2026 In Structure licensing deal, Roche commits $100M to shore up GLP-1 position
FierceBiotech 6. Jan. 2026 Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs
FierceBiotech 6. Jan. 2026 Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator
FierceBiotech 6. Jan. 2026 Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact